Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : National Institute on Aging
Deal Size : Undisclosed
Deal Type : Funding
Details : Funding to support a randomized, double-blind, placebo-controlled pilot study of RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in older adults.
Product Name : RTB101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : National Institute on Aging
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : resTORbio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : TrialSpark's integrated tech platform and trial model will enable resTORbio to accelerate their clinical trials of RTB-101 for COVID-19 in community/outpatient settings.
Product Name : RTB101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : resTORbio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is supported by additional data observed in resTORbio Phase 2b and Phase 3 clinical trials which suggest the potential of RTB101 to reduce the severity of laboratory-confirmed coronavirus infections.
Product Name : RTB101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2020
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dactolisib
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101
Details : Company will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101 alone or in combination with sirolimus, in Parkinson’s disease (PD).
Product Name : RTB101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : Dactolisib
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dactolisib
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, effective in preclinical models to inhibit the activity of TORC1 and induce autophagy.
Product Name : RTB101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2020
Lead Product(s) : Dactolisib
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable